Viatris share price logo

Viatris

NASDAQ: VTRS

Large Cap

$17.44

-0.05

(-0.29%)

as on

Viatris Stock Performance

as on October 9, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $16.89
    $17.52
    downward going graph

    3.15%

    Downside

    0.46%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.69
    $18.43
    downward going graph

    44.44%

    Downside

    5.68%

    Upside

    downward going graph

Viatris share price movements today

Previous Close
$17.49
Open
$17.44
Volume
14.2M
Market Cap
$20.1B
Dividend Yield
2.74%
Day's Low - High
$16.89 - $17.52
52 Week Low - High
$9.69 - $18.43

Viatris Historical Returns

1 Month Return
+ 5.7 %
3 Month Return
+ 6.73 %
1 Year Return
+ 74.57 %
3 Year Return
+ 80.54 %
5 Year Return
+ 27.95 %

Viatris Stock Fundamentals & Key Indicators

Check Viatris market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$20.1B

EPS (TTM)

-0.36

Dividend Yield

2.74%

Quarterly Earnings Growth YOY

-0.71%

PE Ratio (TTM)

-48.58

Industry PE ratio

24.22

PEG Ratio

-3.33

EBITDA

2.7B

Revenue (TTM)

14.7B

Profit Margin

34.83%

Return On Equity TTM

-2.79%

Viatris vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Viatris with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Viatris image
Viatris
Buy$20.1B27.95%-48.5834.83%2.74%
Sandoz Group Ltd Sponsored ADR image
Sandoz Group Ltd Sponsored ADR
Buy$36.9BNA57.0047.54%1.21%
United Therapeutics image
United Therapeutics
Buy$23.4B172.69%18.0386.14%0.00%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
Buy$38.8BNA18.8865.57%1.37%
Zoetis image
Zoetis
Buy$29.5B-63.07%11.7770.87%2.92%

Stock Returns calculator for Viatris Stock including INR - Dollar returns

The Viatris stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Viatris investment value today

Current value as on today

₹1,90,348

Returns

₹90,348

(+90.35%)

Returns from Viatris Stock

₹74,575 (+74.57%)

Dollar Impact

₹15,774 (+15.77%)

Analyst Recommendation on Viatris Stock

Based on 8 analysts

BUY

50.00%

Buy

37.50%

Hold

12.50%

Sell

Based on 8 analysts, 50% of analysts recommend a 'BUY' rating for Viatris. Average target price of $19.7

Viatris Share Price Target

Get share price movements and forecasts by analysts on Viatris.

What analysts predicted

11.47%UPSIDE

Target Price

$19.7

Current Price

$17.44

Analyzed by

8 Analysts

High

$26

Target

$19.70

Low

$13

Viatris target price $19.7, a slight upside of 11.47% compared to current price of $17.44. According to 8 analysts rating.

Indian Investors' Interest in Viatris Stock

Search interest for Viatris Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:10% versus previous 30 day period

Viatris Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3,663
3,796
3,751
3,528
3,254
3,582
3,759
3,703
3,517
3,756
Gross Profit
1,504
1,445
1,459
1,215
1,161
1,332
1,384
1,134
1,157
1,456
Operating Income
203
-239
225
-179
-2,882
233
251
-265
-79
6
EBITDA
1,034
540
905
339
-2,316
577
800
543
643
729
Interest Expense
138
145
145
120
115
116
119
119
120
120
Depreciation
691
786
669
746
664
678
688
766
676
672
Income Before Tax
204
-391
90
-526
-3,097
-217
-7
-343
-247
-64
Income Tax Expense
90
-65
-4
-10
-55
-212
120
-2
-423
54
Net Income
113
-326
94
-516
-3,042
-4
-128
-340
176
-118
Net Profit Margin
41.05%
38.07%
38.90%
34.44%
35.68%
37.21%
36.83%
30.63%
32.90%
38.77%

Viatris Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
11,907
11,433
11,500
11,946
17,886
16,262
15,426
14,739
14,299
Gross Profit
4,783
4,001
3,897
3,796
5,575
6,497
6,438
5,623
5,013
Operating Income
1,437
905
715
-210
-34
1,614
766
10
-2,663
EBITDA
3,243
2,950
2,691
1,992
4,478
6,433
3,516
2,635
-395
Interest Expense
534
542
517
497
636
592
573
550
471
Depreciation
1,805
2,109
2,019
2,216
4,506
3,027
2,740
2,708
2,798
Income Before Tax
903
298
154
-721
-664
2,813
202
-623
-3,665
Income Tax Expense
207
-54
137
-51
604
734
148
11
-150
Net Income
696
352
16
-669
-1,269
2,078
54
-634
-3,514
Net Profit Margin
40.17%
35.00%
33.89%
31.78%
31.17%
39.95%
41.74%
38.15%
35.06%

Viatris Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
113
-326
94
-516
-3,042
-4
-128
-340
176
-118
Operating Cash Flow
614
379
826
482
535
219
744
815
388
381
Investing Cash Flow
-154
375
1,747
-168
-65
-52
-98
-211
277
-51
Financing Cash Flow
-425
-847
-1,636
-1,420
-467
-362
-228
-236
-203
-1,242
Change in Cash
22
-97
961
-1,144
20
-188
435
344
456
-914

Viatris Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
696
352
16
-669
-1,269
2,078
54
-634
-3,514
Operating Cash Flow
2,064
2,341
1,803
1,231
3,016
2,999
2,799
2,302
2,315
Investing Cash Flow
-976
-1,210
-525
-301
-117
1,474
-764
1,800
-427
Financing Cash Flow
-1,893
-1,090
-1,169
-605
-3,012
-3,877
-2,301
-4,330
-1,293
Change in Cash
-777
19
101
358
-143
556
-268
-257
611

Global Institutional Holdings in Viatris

Check out the Institutions with significant holdings in Viatris.

Funds
Holdings
Vanguard
11.01%
VANGUARD INDEX FUNDS
9.51%
Chris Davis
6.55%
iShares
4.55%
SPDR
3.97%
See all

Viatris News & Key Events

  • img

    Today's Timeline - 08 October

    Thu, 05:26 PM

    -

    Viatris agrees to acquire Pacira BioSciences for $1.65 billion, enhancing its non-opioid pain management portfolio.

Insights on Viatris

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, VTRS stock has moved up by 74.6%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, VTRS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, VTRS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.51B → 3.75B (in $), with an average increase of 6.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 176.39M → -118.79M (in $), with an average decrease of 167.4% per quarter

About Viatris

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
OrganisationViatris
HeadquartersRobert J. Coury Global Center, Canonsburg, PA, 15317, US
IndustryDrug Manufacturers - Specialty & Generic
CEOScott Andrew Smith

Key Management of Viatris

Name

Title

Mr. Paul B. Campbell

Interim CFO, Chief Accounting Officer & Corporate Controller

Mr. Philippe Martin

Chief R&D Officer

Mr. Peter McCormick

Chief Supply Officer

Mr. Scott Andrew Smith Ph.D.

CEO & Director

Mr. Andrew Enrietti

Chief Administrative & Transformation Officer

Dr. Corinne M. Le Goff M.B.A., Pharm.D.

Chief Commercial Officer

Ms. Lara Ramsburg

Chief People & Corporate Affairs Officer

Mr. Ramkumar V. Rayapureddy

Chief Information Officer

Mr. William Szablewski C.F.A.

Head of Investor Relations & Capital Markets

Mr. Matthew Joseph Maletta

Chief Legal Officer

FAQs

What is Viatris share price today?

Viatris share price today is $17.44 as on at the close of the market. Viatris share today touched a day high of $17.52 and a low of $16.89.

What is the 52 week high and 52 week low for Viatris share?

Viatris share touched a 52 week high of $18.43 on and a 52 week low of $9.69 on . Viatris stock price today i.e. is closed at $17.44,which is 5.37% down from its 52 week high and 79.98% up from its 52 week low.

What is Viatris's market capitalisation today?

Viatris market capitalisation is $0.02T as on .

How to invest in Viatris Stock (VTRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Viatris on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Viatris Stock (VTRS) from India?

Indian investors can start investing in Viatris (VTRS) shares with as little as ₹96.779998779297 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹967.80 in Viatris stock (as per the Rupee-Dollar exchange rate as on ). Based on Viatris share’s latest price of $17.44 as on October 9, 2026 at 8:46 am IST, you will get 0.5734 shares of Viatris. Learn more about fractional shares .

What are the returns that Viatris has given to Indian investors in the last 5 years?

Viatris stock has given 27.95% share price returns and 28.18% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?